Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s stock price crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $5.81 and traded as high as $8.14. Cumberland Pharmaceuticals shares last traded at $7.51, with a volume of 73,339 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

The company’s 50-day moving average is $7.40 and its 200-day moving average is $5.82. The firm has a market capitalization of $110.70 million, a price-to-earnings ratio of -10.41 and a beta of 0.06.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07). Cumberland Pharmaceuticals had a negative net margin of 34.40% and a negative return on equity of 28.81%. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $8.50 million.

Cumberland Pharmaceuticals Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, July 23rd were paid a dividend of $1.50 per share.

Institutional Trading of Cumberland Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its stake in Cumberland Pharmaceuticals by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock valued at $898,000 after purchasing an additional 4,081 shares in the last quarter. BlackRock Inc. bought a new position in shares of Cumberland Pharmaceuticals during the second quarter worth about $412,000. Bank of New York Mellon Corp acquired a new position in Cumberland Pharmaceuticals in the second quarter worth about $379,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Cumberland Pharmaceuticals in the first quarter worth about $66,000. Institutional investors and hedge funds own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, acquisition and commercialization of prescription products for hospital care, gastroenterology and other targeted therapeutic areas. The company’s business model emphasizes branded medicines that address specific clinical needs and are marketed primarily in the United States.

Its product portfolio has included Acetadote (acetylcysteine injection), used in the treatment of acetaminophen poisoning; Caldolor (ibuprofen injection), an intravenous nonsteroidal anti-inflammatory drug for pain and fever; and Kristalose (lactulose), a prescription treatment for constipation.